10-Q: MAIA Biotech Reports Q3 Loss, Advances Cancer Trials, Adopts Crypto Treasury

MAIA Biotechnology reported increased operating expenses and a net loss for Q3 2025, while advancing its lead cancer drug ateganosine in clinical trials and adopting a new digital asset treasury plan.

Summary

• Net loss for the nine months ended September 30, 2025, was $(18,767,410), a decrease from $(19,682,718) in the prior year period.
• Research and development expenses increased by 80% to $12,665,688 for the nine months ended September 30, 2025, compared to $7,040,145 in the prior year.
• General and administrative expenses increased by 48% to $7,286,726 for the nine months ended September 30, 2025, compared to $4,912,461 in the prior year.
• Cash balance as of September 30, 2025, was $10,891,736, an increase from $9,601,298 at December 31, 2024.
• Working capital as of September 30, 2025, was approximately $1,760,992, a decrease of approximately $4,561,000 from December 31, 2024.
• The company received Fast Track designation from the FDA for ateganosine for the treatment of non-small cell lung cancer (NSCLC).
• Updated Phase 2 THIO-101 clinical trial data for 3L NSCLC patients showed a median overall survival (OS) of 17.8 months and median progression-free survival (PFS) of 5.6 months.
• A patient in the THIO-101 trial demonstrated 30 months (912 days) survival, concluding treatment after 2 years.
• The company entered into clinical supply agreements with BeOne Medicines and Roche for future studies combining ateganosine with their respective immune checkpoint inhibitors.
• The Board of Directors adopted a Digital Asset Treasury Plan (DATP) on October 6, 2025, allowing allocation of up to 90% of corporate treasury reserves to Bitcoin, Ether, and USD Coin.
• Multiple private placements and At-The-Market (ATM) offerings were conducted, raising significant capital throughout the period and subsequently.

Sentiment

Score: 6

Explanation: The sentiment is mixed. Strong clinical data, FDA Fast Track designation, and strategic partnerships are significant positives for the core biopharmaceutical business. However, the persistent 'going concern' warning, increased operating expenses, and the highly speculative and risky new Digital Asset Treasury Plan introduce substantial financial and operational uncertainty, tempering overall positive sentiment.

Positives

• Net loss decreased by 5% for the nine months ended September 30, 2025, compared to the same period in 2024, indicating a slightly improved bottom line.
• FDA granted Fast Track designation for ateganosine for NSCLC, potentially accelerating its development and review process.
• Positive updated data from the THIO-101 Phase 2 clinical trial for 3L NSCLC patients, showing a median overall survival (OS) of 17.8 months and median progression-free survival (PFS) of 5.6 months.
• A patient in the THIO-101 trial achieved 30 months (912 days) survival, highlighting ateganosine's potential for extended dosing and patient benefit.
• New partial response identified in a THIO-101 patient after 20 months of treatment.
• Expansion of the THIO-101 trial into Taiwan, Europe, and Asia, broadening the patient pool for evaluations.
• Secured clinical supply agreements with global oncology companies BeOne Medicines and Roche, providing their immune checkpoint inhibitors (tislelizumab and atezolizumab) at no cost for combination studies, representing significant cost savings.
• European Patent Office granted a broad patent covering ateganosine-based analogues and methods of use, strengthening the company's intellectual property portfolio.
• Successful capital raises through private placements and At-The-Market offerings provided $13,104,175 in financing activities for the nine months ended September 30, 2025, and additional funds subsequently.

Negatives

• The company incurred recurring losses and negative cash flow from operations, accumulating a deficit of $106,002,244 from inception through September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern within one year after the financial statements are issued.
• Working capital decreased by approximately $4,561,000 from December 31, 2024, to September 30, 2025, indicating a weakening liquidity position.
• Research and development expenses increased significantly by 80% for the nine months ended September 30, 2025, reflecting higher costs for clinical and scientific research.
• General and administrative expenses increased by 48% for the nine months ended September 30, 2025, driven by higher professional fees, investor relations, stock-based compensation, and payroll.
• The adoption of a Digital Asset Treasury Plan (DATP) introduces significant market risks associated with digital assets, including price volatility, limited liquidity, and regulatory uncertainty.
• The company has limited history in generating staking revenues from digital assets, making it difficult to forecast future results from this new strategy.
• The company is subject to risks related to the classification of digital assets as securities, which could lead to additional regulation and adverse impacts on the business.

Risks

• Substantial doubt about the company's ability to continue as a going concern within one year due to recurring losses and negative cash flow from operations.
• Failure to secure additional funding through equity or debt financing, or inability to contain expenses, could prevent the company from meeting future working capital needs.
• The launch of central bank digital currencies (CBDCs) may adversely impact the business by reducing demand for private-sector cryptocurrencies.
• Any digital asset acquired by the company may be classified as a security by regulatory bodies, subjecting the company to additional regulation and potentially requiring registration as an investment company under the 1940 Act.
• If deemed an investment company, restrictions imposed by the 1940 Act could make it impractical to continue business as contemplated, adversely affecting operations and financial condition.
• Exposure to regulatory developments related to crypto assets and crypto asset markets, including new laws, regulations, or enforcement actions, could adversely affect the price of digital assets held and the company's business.
• Cryptocurrency assets are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity during market instability.
• Digital assets held with custodians do not enjoy the same protections as cash or securities deposited with federally insured institutions.
• Risk of security breaches or cyberattacks on the company or its third-party service providers, leading to loss of digital assets, reputational harm, and regulatory scrutiny.
• Limited history in generating staking revenues from digital assets makes future prospects and results of operations difficult to forecast.
• Competition from other companies focused on digital asset staking operations could increase, impacting profitability.
• Potential for trade errors in investment and trading activities, which could result in material losses.
• The ongoing wars in Ukraine and Israel may have adverse effects on economic markets, potentially impacting the company's business, financial condition, and results of operations.

Future Outlook

The company plans to seek accelerated approval for ateganosine in the United States for advanced NSCLC in 2026, though this does not guarantee accelerated review or marketing approval. A Phase 3 pivotal trial (THIO-104) is planned for 2025 to evaluate ateganosine with a checkpoint inhibitor in third-line NSCLC patients, potentially leading to early full commercial approval in 2027 and final analysis for full commercial approval in 2028. Phase 2 clinical trials for hepatocellular carcinoma (HCC), colorectal cancer (CRC), and small cell lung cancer (SCLC) are planned to be initiated in 2026. The company also intends to conduct clinical trials for ateganosine in other solid tumors such as breast, prostate, gastric, pancreatic, and ovarian cancers. The at-the-market offering is anticipated to continue, and the Digital Asset Treasury Plan may be utilized for future purchases of Bitcoin, Ether, and USD Coin, subject to liquidity needs and market conditions.

Management Comments

• Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which we discuss under Risk Factors.
• We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
• We have implemented a plan to control our expenses in order to satisfy our obligations due within one year from the date of issuance of these financial statements.
• We cannot guarantee that we will be able to raise additional equity, raise debt, or contain expenses.
• The company chose a name (ateganosine) inspired by the mechanism of action of THIO: altering telomeric guanosine of the cancer cells, aiming to support clear communication between healthcare providers, patients and researchers.
• Management will regularly consult with the Board on cryptocurrency transactions and holdings, cybersecurity procedures, accounting policies, risks, and material developments related to the Digital Asset Treasury Plan.

Industry Context

MAIA Biotechnology operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on oncology drug development. Its lead asset, ateganosine, targets lung cancer and other solid tumors, a significant market with high unmet medical needs. The company's strategy of combining its drug candidate with established immune checkpoint inhibitors from partners like Regeneron, BeOne Medicines, and Roche is a common approach to enhance efficacy and leverage existing therapies. The recent adoption of a Digital Asset Treasury Plan, allowing up to 90% of corporate treasury reserves to be held in cryptocurrencies, represents a significant and unusual diversification for a clinical-stage biopharmaceutical company, introducing a novel and high-risk element to its financial strategy that is outside typical industry norms.

Comparison to Industry Standards

• The reported median overall survival (OS) of 17.8 months for third-line (3L) NSCLC patients in the THIO-101 Phase 2 trial is notably strong compared to historical outcomes for heavily pre-treated 3L NSCLC patients, where median OS with standard chemotherapy typically ranges from 6-10 months. This suggests a potentially significant clinical benefit for ateganosine.
• The median progression-free survival (PFS) of 5.6 months for 3L NSCLC patients also appears favorable when compared to conventional chemotherapy options in this advanced setting, which often yield PFS values in the range of 2-4 months.
• The FDA's Fast Track designation for ateganosine for NSCLC indicates that the agency recognizes the drug's potential to address a serious condition and fulfill an unmet medical need, aligning with regulatory efforts to expedite promising therapies in oncology.
• The company's strategy of partnering with established pharmaceutical companies like Regeneron, BeOne Medicines, and Roche for clinical supply agreements is a common and effective industry practice for clinical-stage biotechs to reduce development costs and gain access to complementary therapies.
• The adoption of a Digital Asset Treasury Plan, allocating up to 90% of corporate treasury to cryptocurrencies, is highly unconventional for a biopharmaceutical company and deviates significantly from standard treasury management practices in the industry, which typically prioritize liquidity and capital preservation in low-risk assets.

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings. From time to time, it may be involved in legal actions and claims arising in the normal course of business, which could have an adverse impact due to defense and settlement costs, diversion of resources, and other factors.

Related Party Transactions

• FGMK, LLC and its affiliate FGMK Business Holdings, LLC, which beneficially owns more than 5% of the company's stock, participated in a Warrant Inducement on September 18, 2025, exercising 243,470 warrants for approximately $317,000.
• FGMK Business Holdings, LLC also participated in a Warrant Amendment on September 29, 2025, reducing the exercise price of certain warrants they hold from $1.87 to $1.30 per share.
• Company directors Stan Smith and Ramiro Guerrero participated in private placements in February, March, and May 2025, purchasing shares and warrants for aggregate prices ranging from $30,000 to $110,000.
• Stan Smith also participated in the June 2025 private placement, purchasing shares and warrants for approximately $50,000.
• Subsequent to the quarter, on October 1, 2025, director Stan Smith purchased 19,230 shares of Common Stock and warrants in a private placement for approximately $25,000.

Stakeholder Impact

• **Shareholders**: Face potential dilution from ongoing equity raises (ATM, private placements) and warrant exercises. The 'going concern' warning indicates significant financial risk. The Digital Asset Treasury Plan introduces high-risk, high-reward exposure to volatile cryptocurrency markets, which could significantly impact share value.
• **Employees**: Increased research and development and general and administrative expenses suggest continued investment in personnel and operations, but the 'going concern' warning implies job security risks if additional funding is not secured.
• **Customers (future patients)**: Positive clinical trial data for ateganosine, FDA Fast Track designation, and expanded clinical programs offer hope for new treatment options for various cancers, particularly NSCLC.
• **Suppliers/Creditors**: The 'going concern' warning and negative cash flow from operations indicate potential risks for timely payment, although recent capital raises provide some liquidity.
• **Regulatory Authorities**: The FDA Fast Track designation and ongoing clinical trials demonstrate compliance with regulatory processes, while the new Digital Asset Treasury Plan may attract increased scrutiny regarding compliance with securities laws.

Next Steps

• Continue enrollment for the THIO-101 Phase 2 expansion trial in the U.S., Europe, and Asia.
• Initiate a Phase 3 pivotal trial (THIO-104) in 2025 to evaluate ateganosine with a checkpoint inhibitor in third-line NSCLC patients.
• Seek filing for accelerated approval of ateganosine in the United States for advanced NSCLC in 2026.
• Initiate Phase 2 clinical trials in HCC, CRC, and SCLC in 2026, evaluating ateganosine with BeOne's tislelizumab.
• Conduct clinical trials evaluating ateganosine in sequential combination with an immune checkpoint inhibitor in other solid tumors (breast, prostate, gastric, pancreatic, ovarian cancers).
• Potentially file for early full commercial approval in 2027 and final analysis for full commercial approval in 2028 based on THIO-104 results.
• Continue at-the-market offering through H.C. Wainwright & Co., LLC.
• Execute purchases of Digital Assets (Bitcoin, Ether, USD Coin) under the newly adopted Digital Asset Treasury Plan, depending on liquidity needs and market conditions.
• Regularly consult with the Board on cryptocurrency transactions, holdings, cybersecurity, accounting policies, risks, and material developments related to the DATP.

Key Dates

Recommendation

The company presents a highly speculative investment profile. On one hand, the clinical data for ateganosine in 3L NSCLC, with a median OS of 17.8 months and a patient achieving 30 months survival, is genuinely promising and the FDA Fast Track designation is a strong positive signal. These developments could drive significant value if successful. On the other hand, the company explicitly states 'substantial doubt about our ability to continue as a going concern' due to recurring losses and negative cash flow, indicating severe financial instability. Furthermore, the adoption of a Digital Asset Treasury Plan, allocating up to 90% of corporate treasury to volatile cryptocurrencies, introduces an entirely new layer of high, unhedged risk that is atypical for a clinical-stage biotech. This dual nature of significant clinical upside potential alongside severe financial risk and a highly speculative treasury strategy makes a 'hold' recommendation appropriate for existing investors who are comfortable with high risk and want to see how the clinical and crypto strategies unfold. New investors should exercise extreme caution due to the 'going concern' warning and the speculative nature of the digital asset strategy.

Keywords

Ateganosine, THIO, NSCLC, Non-Small Cell Lung Cancer, Oncology, Immunotherapy, Clinical Trials, Phase 2, Phase 3, Fast Track Designation, Biotechnology, Biopharmaceutical, Digital Assets, Cryptocurrency, Bitcoin, Ether, USD Coin, Treasury Management, SEC Filing, 10-Q, Going Concern, Capital Raise, Warrants, Private Placement, ATM Offering, Regeneron, BeOne Medicines, Roche, Patent